A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children

Inclusion Criteria Concurrent Medication: Allowed: IVIG. Prophylaxis for opportunistic infection. EPO. G-CSF or GM-CSF. Patients must have: Symptomatic HIV infection. Less than 56 days of prior antiretroviral therapy. Consent of parent or guardian. NOTE: Co-enrollment on ACTG 219, ACTG 220, and certain ACTG opportunistic infection protocols is permitted. Prior Medication: Allowed: Up to 56 days of prior antiretroviral therapy. Prior immunomodulator therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Malignancy. Hypersensitivity to a nucleoside analog. Current grade 2 or higher amylase/lipase toxicity or grade 3 or 4 other toxicity. PER AMENDMENT 4/29/96: Active opportunistic infection and/or serious bacterial infection at the time of entry. Concurrent Medication: Excluded: Any other anti-HIV therapy. Megestrol acetate ( Megace ). Probenecid. IV pentamidine. Human growth hormone ( hGH ). Systemic corticosteroids for more than 2 weeks. Prior Medication: Excluded: Investigational drug therapy within 14 days prior to study entry.